Axial Spondyloarthritis Treatment Recommendations in 2024: Where Are We Now?

Authors

  • Sherry Rohekar, BSc, MD, FRCPC, MSc (Clin. Epi) Western University, London, Ontario

DOI:

https://doi.org/10.58931/crt.2024.1252

Abstract

As 2024 continues to evolve, so do treatment recommendations for the management of spondyloarthritis (SpA), including ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). From a Canadian perspective, we eagerly await the publication of the Canadian Rheumatology Association (CRA)/Spondyloarthritis Research Consortium of Canada (SPARCC) Living Treatment Recommendations for the Management of Axial Spondyloarthritis (axSpA), currently in press. Until these recommendations for axSpA treatment with a Canadian perspective arrive  – where are we now?

Author Biography

Sherry Rohekar, BSc, MD, FRCPC, MSc (Clin. Epi), Western University, London, Ontario

Dr. Sherry Rohekar completed medical school at the University of Western Ontario, and then went on to train in general internal medicine at Queen’s University and rheumatology at the University of Toronto. She also has a Master’s of Clinical Epidemiology from UWO. She is now an Associate Professor in the Department of Medicine, Division of Rheumatology at UWO. Her research and clinical interest is spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis. She is currently on the executive committee the SPondyloArthritis Research Consortium of Canada, and member of the International Psoriasis and Arthritis Research Team, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and the SPondyloArthritis Research & Treatment Network.

References

Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2019;71(10):1285–1299. doi: 10.1002/acr.24025 DOI: https://doi.org/10.1002/acr.24025

Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19–34. doi: 10.1136/ard-2022-223296 DOI: https://doi.org/10.1136/ard-2023-223937

Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–926. doi: 10.1136/bmj.39489.470347.AD DOI: https://doi.org/10.1136/bmj.39489.470347.AD

Centre for Evidence-Based Medicine. Oxford Centre for Evidence-Based Medicine:The Oxford 2009 levels of evidence. [Updated: 2024, Cited: 14 Jun 2024]. Available at: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-forevidence- based-medicine-levels-of-evidence-march-2009.

Sinnappan S, Forte A, Ermann J. Axial spondyloarthritis treatment recommendations and disease activity monitoring in clinical practice: results of an online survey. J Rheumatol. 2024;51(5):472–478. doi: 10.3899/jrheum.2023-0894. DOI: https://doi.org/10.3899/jrheum.2023-0894

Akl EA, Meerpohl JJ, Elliott J, Kahale LA, Schünemann HJ, Living Systematic Review Network. Living systematic reviews: 4. Living guideline recommendations. J Clin Epidemiol. 2017;91:47–53. doi: 10.1016/j.jclinepi.2017.08.009 DOI: https://doi.org/10.1016/j.jclinepi.2017.08.009

Elliott JH, Synnot A, Turner T, Simmonds M, Akl EA, McDonald S, et al. Living systematic review: 1. Introduction-the why, what, when, and how. J Clin Epidemiol. 2017;91:23–30. doi: 10.1016/j.jclinepi.2017.08.010 DOI: https://doi.org/10.1016/j.jclinepi.2017.08.010

Hazlewood GS, Pardo JP, Barnabe C, Schieir O, Barber CEH, Proulx L, et al. Canadian Rheumatology Association living guidelines for the pharmacological management of rheumatoid arthritis with disease-modifying anti-rheumatic drugs [version 2.1]. [Internet]. [cited 25 Nov 2023]. Available from: https://app.magicapp.org/#/guideline/7413

Downloads

Published

2024-09-17

How to Cite

1.
Rohekar S. Axial Spondyloarthritis Treatment Recommendations in 2024: Where Are We Now?. Can Rheumatol Today [Internet]. 2024 Sep. 17 [cited 2024 Dec. 21];1(2):41–46. Available from: https://canadianrheumatologytoday.com/article/view/1-2-Rohekar

Issue

Volume 1, Issue 2, Summer 2024

Section

Articles

License

Copyright (c) 2024 Canadian Rheumatology Today

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.